Cotinga Pharmaceuticals Inc. (COTQF)
Cotinga Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,199. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of -9.29 implies it has historically moved less than the broad market.
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.
Cotinga Pharmaceuticals Inc. is most often compared with the following Healthcare names: